从2017年美国临床肿瘤学会大会报告看早期乳腺癌治疗加减法

被引：2

作者：

王殊

彭媛

机构：

[1] 北京大学人民医院乳腺中心

来源：

山东大学学报(医学版) | 2018年 / 56卷 / 01期

关键词：

早期乳腺癌; 美国临床肿瘤学会; 治疗进展; 化疗; 内分泌治疗; 靶向治疗;

D O I：

暂无

中图分类号：

R737.9 [乳腺肿瘤];

学科分类号：

100214 [肿瘤学];

摘要：

乳腺癌的治疗正朝着精准医疗的方向迈进。2017年美国临床肿瘤学会大会报告围绕着乳腺癌治疗的加减法进行了充分的讨论,就早期乳腺癌的治疗,从传统的手术治疗、化疗、内分泌治疗,到靶向治疗和新治疗靶点的发现,均有新的临床试验结果更新,为给不同患者制定有效、损伤小且经济的治疗方案提供了新的依据。

引用

页码：17 / 21

页数：5

共 7 条

[1]

The BRCA1 ness signature is associated significantly with response to PARP inhibitor treatment versus control in the I-SPY 2 randomized neoadjuvant setting.[J].Tesa M. Severson;Denise M. Wolf;Christina Yau;Justine Peeters;Diederik Wehkam;Philip C. Schouten;Suet-Feung Chin;Ian J. Majewski;Magali Michaut;Astrid Bosma;Bernard Pereira;Tycho Bismeijer;Lodewyk Wessels;Carlos Caldas;René Bernards;Iris M. Simon;Annuska M. Glas;Sabine Linn;Laura van ‘t Veer.Breast Cancer Research.2017, 1

[2]

Neratinib for the treatment of HER2-positive early stage breast cancer [J].

Echavarria, Isabel ;

Lopez-Tarruella, Sara ;

Marquez-Rodas, Ivan ;

Jerez, Yolanda ;

Martin, Miguel .

EXPERT REVIEW OF ANTICANCER THERAPY, 2017, 17 (08) :669-679

[3]

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response [J].

de Azambuja, Evandro ;

Holmes, Andrew P. ;

Piccart-Gebhart, Martine ;

Holmes, Eileen ;

Di Cosimo, Serena ;

Swaby, Ramona F. ;

Untch, Michael ;

Jackisch, Christian ;

Lang, Istvan ;

Smith, Ian ;

Boyle, Frances ;

Xu, Binghe ;

Barrios, Carlos H. ;

Perez, Edith A. ;

Azim, Hatem A., Jr. ;

Kim, Sung-Bae ;

Kuemmel, Sherko ;

Huang, Chiun-Sheng ;

Vuylsteke, Peter ;

Hsieh, Ruey-Kuen ;

Gorbunova, Vera ;

Eniu, Alexandru ;

Dreosti, Lydia ;

Tavartkiladze, Natalia ;

Gelber, Richard D. ;

Eidtmann, Holger ;

Baselga, Jose .

LANCET ONCOLOGY, 2014, 15 (10) :1137-1146

[4]

6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial [J].

Pivot, Xavier ;

Romieu, Gilles ;

Debled, Marc ;

Pierga, Jean-Yves ;

Kerbrat, Pierre ;

Bachelot, Thomas ;

Lortholary, Alain ;

Espie, Marc ;

Fumoleau, Pierre ;

Serin, Daniel ;

Jacquin, Jean-Philippe ;

Jouannaud, Christelle ;

Rios, Maria ;

Abadie-Lacourtoisie, Sophie ;

Tubiana-Mathieu, Nicole ;

Cany, Laurent ;

Catala, Stephanie ;

Khayat, David ;

Pauporte, Iris ;

Kramar, Andrew .

LANCET ONCOLOGY, 2013, 14 (08) :741-748

[5]

Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS; a randomised trial.[J].Christina Davies;Hongchao Pan;Jon Godwin;Richard Gray;Rodrigo Arriagada;Vinod Raina;Mirta Abraham;Victor Hugo Medeiros Alencar;Atef Badran;Xavier Bonfill;Joan Bradbury;Michael Clarke;Rory Collins;Susan R Davis;Antonella Delmestri;John F Forbes;Peiman Haddad;Ming-Feng Hou;Moshe Inbar;Hussein Khaled;Joanna Kielanowska;

[6]

Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial [J].